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Abstract
Background: Runt-related transcription factor 2 (RUNX2) haploinsufficiency causes cleidocranial dysplasia (CCD)
which is characterized by supernumerary teeth, short stature, clavicular dysplasia, and osteoporosis. At present, as
a therapeutic strategy for osteoporosis, mesenchymal stem cell (MSC) transplantation therapy is performed in
addition to drug therapy. However, MSC-based therapy for osteoporosis in CCD patients is difficult due to a
reduction in the ability of MSCs to differentiate into osteoblasts resulting from impaired RUNX2 function. Here, we
investigated whether induced pluripotent stem cells (iPSCs) properly differentiate into osteoblasts after repairing the
RUNX2 mutation in iPSCs derived from CCD patients to establish normal iPSCs, and whether engraftment of
osteoblasts derived from properly reverted iPSCs results in better regeneration in immunodeficient rat calvarial
bone defect models.
Methods: Two cases of CCD patient-derived induced pluripotent stem cells (CCD-iPSCs) were generated using
retroviral vectors (OCT3/4, SOX2, KLF4, and c-MYC) or a Sendai virus SeVdp vector (KOSM302L). Reverted iPSCs were
established using programmable nucleases, clustered regularly interspaced short palindromic repeats (CRISPR)/Cas-
derived RNA-guided endonucleases, to correct mutations in CCD-iPSCs. The mRNA expressions of osteoblast-specific
markers were analyzed using quantitative reverse-transcriptase polymerase chain reaction. iPSCs-derived osteoblasts
were transplanted into rat calvarial bone defects, and bone regeneration was evaluated using microcomputed
tomography analysis and histological analysis.
Results: Mutation analysis showed that both contained nonsense mutations: one at the very beginning of exon 1 and
the other at the initial position of the nuclear matrix-targeting signal. The osteoblasts derived from CCD-iPSCs (CCD-OBs)
expressed low levels of several osteoblast differentiation markers, and transplantation of these osteoblasts into calvarial
bone defects created in rats with severe combined immunodeficiency showed poor regeneration. However, reverted
iPSCs improved the abnormal osteoblast differentiation which resulted in much better engraftment into the rat calvarial
bone defect.
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Conclusions: Taken together, these results demonstrate that patient-specific iPSC technology can not only provide a
useful disease model to elucidate the role of RUNX2 in osteoblastic differentiation but also raises the tantalizing prospect
that reverted iPSCs might provide a practical medical treatment for CCD.
Keywords: Cleidocranial dysplasia, RUNX2, iPSCs, Osteoblasts, Osteogenesis, CRISPR/Cas,
Background
Cleidocranial dysplasia (CCD) is a dominantly inher-
ited disorder characterized by patent fontanelles, wide
cranial sutures, hypoplasia of the clavicles, short stat-
ure, and supernumerary teeth. In addition, other skel-
etal anomalies and osteoporosis are common [1, 2].
Runt-related transcription factor 2 (RUNX2), the gene
responsible for CCD [3–5], encodes a transcription
factor that is a member of the runt family of proteins
[6]. These proteins contain a DNA-binding domain
highly homologous to the Drosophila pair-rule gene
runt [7]. In particular, RUNX2 is essential for the
commitment of pluripotent mesenchymal cells toward
osteoblasts (OBs), the bone-forming cells [8]. Some of
the mutations found in CCD have been shown to
interfere with the DNA-binding activity of RUNX2,
whereas others have been found to alter the nuclear
localization of the protein or to produce a mutant or
truncated protein that is biologically inactive [9–11].
Runx2 gene expression must be tightly regulated to
support skeletal health, although sufficient activity is
necessary for adequate osteogenesis because reduced
or excessive Runx2 activity may lead to osteoporosis
[12]. Mice that are deficient in RUNX2 have complete
absence of bone [5, 13, 14], while those with haploin-
sufficiency of this transcription factor mimic some of
the human CCD phenotypes, while others, such as
supernumerary teeth, some skeletal abnormalities, and
osteoporosis, have not been clearly demonstrated in
mice [13].
Osteoporosis is a debilitating disease caused by
systemic bone loss in the musculoskeletal system. Other
than the anabolic parathyroid hormone drug, current
Food and Drug Administration (FDA)-approved treat-
ments are predominant agents that aim to inhibit bone
resorption and prevent further bone loss. These types of
treatment are associated with serious side effects and
consequently there is a call for an alternative approach
to treat osteoporosis [15]. The number of clinical trials
involving mesenchymal stem cell (MSC)-based therapy
has increased markedly over the last decade. This is
because MSCs are multipotent adult stem cells that can
be easily procured from various sources, such as bone
marrow, adipose, and cord blood tissue [16].
However, in osteoporosis, the number of bone marrow
MSCs that can differentiate into osteoblasts and form
bone is significantly reduced. In addition, MSC derived
from CCD patients seems to have a decreased ability to
induce differentiation into osteoblasts due to haploinsuf-
ficiency of RUNX2.
Human induced pluripotent stem cells (hiPSCs)
provide an iPSC-based novel disease model as well as a
therapeutic option for the treatment of CCD [17]. We
previously reported an efficient method to differentiate
hiPSCs into osteogenic lineage cells [18] that supported
the notion to generate CCD patient-derived iPSCs to
elucidate the pathophysiology of CCD.
However, patient-derived iPSCs contain genetic
mutations and exhibit poor osteogenic differentiation
capability. Furthermore, hiPSCs have different genetic
backgrounds and could exhibit heterogeneity, thereby
limiting their use as model systems [19]. A technique
has been developed to correct the defective gene in
patient-derived iPSCs using programmable nucleases,
i.e., clustered regularly interspaced short palindromic
repeats (CRISPR)/Cas-derived RNA-guided endonucle-
ases, which is now widely used for genomic editing of
higher eukaryotic cells [20]. In this RNA-guided nucle-
ase system, a user-defined single-guide RNA (sgRNA)
directs the endonuclease Cas9 to a specific genomic
target, where it cleaves chromosomal DNA. This cleav-
age activates endogenous cellular DNA repair pathways
in a process known as homologous recombination,
which gives rise to targeted correction of mutated genes
[21]. In this report, we show the successful correction
of the mutated RUNX2 gene, and show that this gen-
etic correction gives rise to normal osteogenic potential
in patient-derived iPSCs. Our evidence clearly reveals
that reverted iPSCs could be used as a source for
regeneration therapy.
Herein, we report the generation of two types of
CCD patient-derived iPSCs, one with a heterozygous
loss of DNA-binding activity of RUNX2 and another
which supposedly alters nuclear localization of the
RUNX2 protein. Both types showed impaired osteo-
differentiation capabilities. We further generated
reverted iPSCs to restore the proper osteodifferentia-
tion potential not only in vitro but also in vivo. These
iPSCs should prove valuable for elucidating disease
mechanisms and providing an iPSC-based novel
therapeutic option for the treatment of CCD or other
diseases related to the Runx2 gene.
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Methods
Cell culture
All experimental procedures described in this manu-
script were approved by the Ethics Committee of Tokyo
Dental College (permit no. 533). Primary human oral
fibroblasts (OFs) were prepared from oral mucosal tissue
(5 × 10 mm) resected from CCD patients, which were
then cultured and subjected to reprogramming by infect-
ing with retroviral vectors (OCT3/4, SOX2, KLF4, and
c-MYC) or a Sendai virus SeVdp vector (KOSM302L) as
described previously [22–24]. All iPSCs were maintained
in human embryonic stem cell (ESC) media (Dulbecco’s
modified Eagle’s medium/nutrient mixture F-12 +
GlutaMAX media supplemented with 20% knockout
serum replacement media, 1% L-glutamine, 1% nones-
sential amino acids, 1% penicillin–streptomycin, 0.1 mM
2-mercaptoethanol, and 5 ng/ml fibroblast growth factor
(FGF)-2).
The efficient method of differentiating hiPSCs into
osteogenic lineage cells is shown in our previous study
[18] as well as in Fig. 2a. For osteoblast differentiation,
cells were cultured in osteoblast differentiation medium
(OBM), which consisted of alpha-MEM supplemented
with 10% fetal bovine serum (FBS), 50 mg/ml L-ascorbic
acid, 10 mM β-glycerophosphate, and 10 nM dexa-
methasone, supplemented with cytokines (25 ng/ml
FGF-2, 1 ng/ml transforming growth factor (TGF)-β1,
100 ng/ml insulin-like growth factor (IGF)-1) for 12
days. OBM containing fresh cytokines was resupplied
every 3 days.
Primary human osteoblasts (HOBs) derived from
normal bone tissue were purchased from Takara Bio Inc.
(Shiga, Japan) and cultured in osteoblast growth medium
(Takara Bio Inc.).
Mutation analysis
Exons 1–7 of the RUNX2 gene were amplified by poly-
merase chain reaction (PCR) under standard conditions
for analyzing CCD case 1 (CCD1) and CCD case 2
(CCD2). The primers used for genomic PCR amplifica-
tion and sequencing are described elsewhere [25].
CRISPR/sgRNA design and construction
We explored the sgRNA using the CRISPRdirect
bioinformatics tool against the human RUNX2 locus
located on chromosome 6. Complete sequences of the
target sites of the sgRNA are provided in Fig. 1g. The
targeting donor vector was constructed based on a
DT-A/conditional knockout FW plasmid (RIKEN Center
for Developmental Biology, Kobe, Japan) with several
modifications. The PCR-amplified fragments from gen-
omic DNA of a healthy individual were inserted into the
restriction enzyme-digested plasmid.
CRISPR/sgRNA transfections for reversion in iPSCs
Transfection of the CRISPR/sgRNA plasmid into iPSCs
was performed as described previously [26]. Electropor-
ation was performed using a Neon Transfection System
(Thermo Fisher Scientific, Waltham, MA, USA)
according to the manufacturer’s instructions. Briefly,
iPSCs were harvested by treating with 0.05% trypsi-
n-ethylenediaminetetraacetic acid (EDTA) solution
(Thermo Fisher Scientific). Cells (1 × 106) were sus-
pended in 100 μl electroporation buffer containing 5 μg
of the donor plasmid and 5 μg of the CRISPR/sgRNA
expression plasmid, and electroporated (condition: 1050
V, 20 ms, two pulses). After electroporation, the cells
were subsequently plated on an iMatrix-511 (Nippi Inc.,
Tokyo, Japan)-coated 100-mm dish and cultured in
StemFit® AK01 medium (Ajinomoto, Tokyo, Japan)
supplemented with ROCK inhibitor (Y-27632; Wako
Pure Chemical Industries Ltd.) for the first 24 h. Genet-
icin selection (300 μg/ml) was started 72 h after electro-
poration. Individual colonies were picked and expanded
for 10 days after electroporation.
RNA isolation, reverse transcriptase PCR, and quantitative
PCR
Total RNA was extracted using QIAzol reagent (Qiagen,
Hilden, Germany) according to the manufacturer’s
instructions. Complementary DNA (cDNA) was synthe-
sized using a high-capacity cDNA reverse transcription
kit (Thermo Fisher Scientific). To confirm the expres-
sion of markers of ESCs and three germ layers, PCR was
performed with Ex-Taq polymerase (Takara Bio, Inc.).
β-actin was used as an internal control. All primer sets
are described elsewhere [24]. Quantitative reverse tran-
scriptase (qRT)-PCR was performed using Premix
Ex-Taq reagent (Takara Bio, Inc.) according to the
manufacturer’s instructions. 18S rRNA was used as an
internal control. All primer sequences are shown in
Table 1. The relative expression of genes of interest was
estimated using the ΔΔCt method.
Immunofluorescent staining
Cells cultured on cover glasses were fixed in 4% parafor-
maldehyde in phosphate-buffered saline (PBS) for 15
min, permeabilized with ice-cold 100% methanol for 10
min at −20 °C, and then blocked with 5% normal goat
serum/0.3% Triton X-100 in PBS for 1 h. Subsequently,
the cells were incubated with anti-RUNX2 antibody (di-
lution 1:1600; Cell Signaling Technology, Inc., Beverly,
MA, USA), followed by Alexa Fluor® 488-conjugated
goat anti-rabbit or mouse immunoglobulin G.
Localization of the RUNX2 protein was visualized by
immunofluorescent microscopy (UPM AxiophoT2; Carl
Zeiss Microscopy, LLC, Thornwood, NY, USA).
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Preparation of scaffold/iPSC-derived OB complex for
transplantation
Osteogenic differentiation from iPSCs was performed
according to Fig. 3a. After 4 weeks, the iPSC-derived
OBs were dissociated with 0.5 mg/ml collagenase type
IV for 30 min and 0.25% trypsin-EDTA for 5 min at 37 °
C. To facilitate the self-assembly of a peptide nanofiber
scaffold-derived three-dimensional (3D) culture, we used
PuraMatrix (BD Biosciences, Cambridge, MA, USA) to
encapsulate the cells; 10 μl of freshly dissociated cells (2
× 105) suspended in serum-free media was mixed with
10 μl of the 2.5% PuraMatrix. Gelation was initiated after
the peptide solution was mixed with the cell suspension,
thereby resulting in cell encapsulation inside the nanofi-
ber hydrogel.
Transplantation of scaffold/iPSC-derived OB complex
All procedures performed with live animals conformed
to the ethical guidelines established by the Japanese
Council on Animal Care and were approved by the
Animal Care Committee of Tokyo Dental College
(permit no. 290401). Seven-week-old male F344/NJcl-
rnu/rnu rats were obtained from Clea Japan, Inc. (Tokyo,
Japan). After anesthesia induction with 4% sevoflurane
(Maruishi Pharmaceutical Co. Ltd., Osaka, Japan) inhal-
ation, the rats were further anesthetized by intraperitoneal
injection with sodium pentobarbital (30 mg/kg body
weight; somnopentyl; Kyoritsu Seiyaku, Tokyo, Japan). Rat
calvarial bone defects were created as previously described
[27]. Scaffold/iPSC-derived OB complex was injected into
the bone defect. The rats receiving transplantation were
sacrificed at 4 weeks and subjected to radiographical and
histological analyses.
Radiographical analyses and histological assessment
Microcomputed tomography (CT) parameters were as
follows: X-ray source, 90 kV/100 μA; rotation, 360°;
exposure time, 17 s; and voxel size, 50 × 50 × 50 μm
(R-μCT®; Rigaku Corporation, Tokyo, Japan). CT
images were compiled and three-dimensional images
were rendered using the TRI/3D-BON system (Ratoc
System Engineering Co. Ltd., Tokyo, Japan) as
described previously [27]. Coronal sections (thickness
= 5 μm) through the center of each circular defect
were prepared and Villanueva–Goldner (V–G) staining
[28] was performed.
Statistical analysis
All data are expressed as the mean ± standard devi-
ation (SD). When analysis of variance indicated differ-
ences among the groups, multiple comparisons
among the experimental groups were performed using
(See figure on previous page.)
Fig. 1 Generation of cleidocranial dysplasia (CCD) patient-specific iPSCs and genome editing. a Identification of heterozygous runt-related transcription
factor 2 (RUNX2) mutations in each CCD. b Functional domains of RUNX2 proteins and RUNX2 exon organization. c Morphology of established CCD
patient-derived induced pluripotent stem cells (CCD-iPS). d–f Confirmation of the pluripotency of the CCD-iPSCs. d RT-PCR analysis of ESC marker
genes. e RT-PCR analyses of various differentiation markers for the three germ layers. Target genes included AFP, FOXA2, and SOX17 (endoderm), T and
MSX1 (mesoderm), and MAPs (ectoderm). β-actin was used as an internal control. f Teratoma formation and histology. Teratoma contained tissues of
three embryonic germ layers: cartilage (mesoderm), gut-like epithelium tissues (endoderm), and neural tube-like structures (ectoderm). g Karyotype
analysis (Q-band) of CCD1- and CCD2-iPSCs. h Clustered regularly interspaced short palindromic repeats (CRISPR)/single-guide RNA (sgRNA) targeting
of the RUNX2 gene on chromosome 6. i CRISPR-mediated genome editing of CCD1-iPSCs. j Confirmation of the RUNX2 gene correction by sequence
analysis. k Confirmation of the pluripotency of the Reverted iPSCs (Rev1-iPSCs). l Karyotype analysis (Q-band) of Rev1-iPSCs. Abbreviations: D, differentiated;
U, undifferentiated; Q/A, glutamine/alanine-rich domain; RHD, runt homology domain; NLS, nuclear localization signal; NMTS, nuclear matrix-targeting
signal; FRT, flippase recognition target; PGK, phosphoglycerate kinase
Table 1 Primers used for quantitative reverse transcriptase polymerase chain reaction
Gene symbol GenBank accession no. Forward primer sequence Reverse primer sequence
RUNX2 NM_001024630.2 gtgcctaggcgcatttca gctcttcttactgagagtggaagg
ALP NM_000478.3 caaccctggggaggagac gcattggtgttgtacgtcttg
COL1A1 NM_000088.3 gggattccctggacctaaag gggattccctggacctaaag
OSX NM_152860.1 catctgcctggctccttg caggggactggagccata
OC NM_199173.3 tgagagccctcacactcctc acctttgctggactctgcac
MSX2 NM_002449.4 tcggaaaattcagaagatgga caggtggtagggctcatatgtc
DLX5 NM_005221.5 ctacaaccgcgtcccaag gccattcaccattctcacct
DLX3 NM_005220.2 gagcctcctaccggcaatac tcctccttcaccgacactg
TWIST1 NM_000474.3 agctacgccttctcggtct ccttctctggaaacaatgacatc
18SrRNA M11188.1 cggacaggattgacagattg cgctccaccaactaagaacg
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the Bonferroni test. Statistical significance was defined
as p < 0.05.
Results
Sequencing analysis of the genomic DNA extracted from
the CCD-OFs revealed a heterozygous nonsense mutation
(R391X as CCD1, Q67X as CCD2) in the RUNX2 gene
(Fig. 1a). This mutation corresponds with the functional
domain of the RUNX2 protein, nuclear matrix-targeting
signal (NMTS) (CCD1), and the glutamine/alanine-rich
domain (Q/A) (CCD2) (Fig. 1b). More than three iPSC
lines were established and analyzed for each CCD patient.
Patient-specific iPSCs from CCD-OFs (Fig. 1c) were gen-
erated using retroviral or Sendai viral vectors that encode
the four Yamanaka factors [23, 24]. All the retroviral or
Sendai viral iPSC lines suppressed transgenes (data not
shown). The pluripotency of the CCD-iPSC lines was con-
firmed as shown in Fig. 1d–f. CCD-iPSCs displayed basic
properties of pluripotent cells, as indicated by the expres-
sion of the embryonic stem cell markers OCT3/4,
NANOG, and REX1 (Fig. 1d), the expression of the three
germ-layer differentiation markers in embryoid bodies
(Fig. 1e), the ability to form teratomas (Fig. 1f), and a
normal karyotype (Fig. 1g). Reverted iPSC (Rev1-iPSC)
lines were generated using CRISPR/Cas9-derived RNA--
guided endonucleases (Fig. 1h, i). RUNX2 gene correction
was confirmed by sequence analysis (Fig. 1j). Rev1-iPSCs
were maintained in a pluripotent state, as indicated by the
expression of the pluripotency markers, and displayed the
ability to form teratomas (Fig. 1k), and a normal karyotype
(Fig. 1l).
Osteogenic differentiation from iPSCs was performed
according to our previous report [18] and Fig. 2a.
CCD-OBs showed a decrease in the nuclear localization
of RUNX2 (Fig. 2b). However, RUNX2 localization was
restored in Rev1-OBs to the same level as normal pri-
mary HOBs (Fig. 2b). Furthermore, we examined Runx2
localization in calvarial OBs derived from Runx2 wild-
type (Runx2+/+) and heterozygous knock-out (Runx2+/–)
mice. As a result, Runx2 localization was decreased in
Runx2+/–-OBs compared to Runx2+/+-OBs (Additional
file 1: Figure S1). We determined the expression of
OB-specific markers to confirm OB differentiation. As
expected, in OBM with FGF-2, TGF-β1, and IGF-1
greatly increased the alkaline phosphatase (ALP) activity
of Rev1-iPSCs, but not CCD1-iPSC, in a time-dependent
manner (Fig. 2c). Furthermore, we examined ALP activ-
ity of primary HOBs and mouse OBs (mOBs) as con-
trols. As a result, the ALP activity of Rev1-iPSCs
cultured in OBM for 12 days was at the same level as
HOBs and Runx2+/+-mOBs. On the other hand, the ALP
activity of Runx2+/–-mOBs was decreased similarly to
CCD1-iPSCs (Additional file 2: Figure S2). As compared
with that in CCD1-iPSCs, the expression levels of the
OB-specific markers ALP, OSX, and OC were markedly
upregulated only in Rev1-iPSCs cultured in OBM for 9
days (Fig. 2d). The mRNA expression level of RUNX2
was higher in CCD1-iPSCs than in Rev1-iPSCs (Fig. 2e).
We next investigated major homeodomain (HD) pro-
teins in osteogenesis, such as DLX5, DLX3, MSX2, and
TWIST1 [29]. The expression levels of DLX5, MSX2,
and TWIST1 mRNA molecules were sharply increased
in Rev1-iPSCs cultured in OBM after 9 days, but not in
CCD1-iPSCs (Fig. 2e). The expression level of DLX3 was
higher in CCD1-iPSCs than in Rev1-iPSCs (Fig. 2e).
These observations indicated that the osteolineage
differentiation of CCD1-iPSCs was significantly delayed,
relative to that of Rev1-iPSCs.
MicroCT images of the calvaria at 4 weeks after trans-
plantation are shown in Fig. 3b. Re-ossification devel-
oped via growth extension from the bony rims at the
lateral edges of the bone defects. Newly generated bone
was observed 4 weeks after surgery in the Rev group.
Minimal new bone was observed in the two CCD groups
(Fig. 3b). The bone volume (BV) and bone mineral con-
tent (BMC) were significantly higher in the Rev group
than in the CCD groups (Fig. 3c). On the other hand,
there was no difference in bone mineral density (BMD)
(Fig. 3c). Histological examination by V–G staining pro-
vides uniform and reproducible results with mineralized
or undecalcified bone. Mineralized bone tissues are
stained green and nonmineralized osteoid tissues are
stained red by V–G stain (Fig. 3d). Newly formed bone
was observed around the margin and along the intracra-
nial periosteum, as well as in the center of the bone de-
fects, including around the top portion of the defect area
in the Rev group. In the CCD groups, there was com-
paratively less newly formed bone (Fig. 3d), indicating
that CCD-iPSCs may have delayed osteodifferentiation.
Discussion
In this study we present two major results. First, we
successfully corrected the mutated Runx2 gene in iPSCs
using the CRISPR/Cas method. Second, the reverted
iPSCs that we generated exhibited better osteogenic
properties both in vivo and in vitro, suggesting that
these iPSCs provide not only an ideal source for study-
ing CCD but also provide an iPSC-based novel thera-
peutic option for the treatment of CCD or other
diseases related to the RUNX2 gene.
We showed that CCD-iPSCs were found to have poor
osteogenic differentiation capability, as the expression
levels of transcription factors important for osteodiffer-
entiation (i.e., HD protein, OSX, TWIST1, MSX2, and
DLX5) were not increased in the proper manner
observed in Rev-iPSCs cultured in OBM after 9 days. An
in vivo experiment (calvarial defects model) revealed the
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poor regeneration capability of CCD-OBs relative to that
of Rev-OBs.
In the present study, two types of CCD-iPSC derived
from patients enrolled in this study were generated and
each had a stop codon insertion mutation in the Q/A-
rich domain or NMTS domain. Nonsense mutation in
the Q/A-rich domain resulted in complete loss of runt
domain, which is a responsive sequence for binding to
Runx2 target cic-element. On the other hand, NMTS is
an important domain for nuclear localization [30].
Deficiency of this domain significantly impeded nuclear
localization of RUNX2 and reduced the coordinated
action of the Smad signaling [30, 31]. These Runx2 func-
tions were some of the most important functional
domains in the Runx2 gene. The deficiency of any do-
main similar to a loss of function of the transcription
factor of RUNX2 has been reported to result in failure
of bone and cartilage differentiation [30–33]. Similarly,
we found that the osteodifferentiation capability of the
two cases of CCD-iPSCs we examined were poor.
We showed that Rev-iPSCs, which could have restored
the proper osteodifferentiation potential, were generated
by the CRISPR/Cas method. We sequenced and con-
firmed the corrected mutated sequence. These Rev-iPSCs
still maintained pluripotencies but gained better osteo-
genic abilities. iPSCs provide an attractive platform for the
study of rare diseases, including CCD. Patient-derived
iPSCs have great potential as a disease model because they
(See figure on previous page.)
Fig. 2 Osteoblastic differentiation of induced pluripotent stem cells (iPSCs) in vitro. a Schedule of osteogenic differentiation. b Runt-related transcription
factor 2 (RUNX2) localization by immunofluorescent microscopy. Single cells from embryoid bodies (EBs) were cultured with osteoblast differentiation
medium (OBM) containing cytokines for 12 days and stained for RUNX2 (green) and the nuclei (blue). c Staining of alkaline phosphatase (ALP) activity
(days (d)0, 3, 6, 9, and 12). d qRT-PCR analysis of RUNX2 target genes. e qRT-PCR analysis of RUNX2 and transcription factors. Values are presented as the
mean ± SD (n = 3). *p < 0.05. FGF fibroblast growth factor, HOB human osteoblast, IGF insulin-like growth factor, TGF transforming growth factor
Fig. 3 Transplantation of induced pluripotent stem cell (iPSC)-induced osteoblasts (OBs) and bone regeneration. a Transplantation protocol for rat
calvarial bone defects. b MicroCT images of the calvaria at 4 weeks after transplantation in the CCD1, CCD2, and Rev1 groups (n = 3). c MicroCT
analysis of bone regeneration. Comparison of new bone volume (cm3) in the regions of interest of three groups. Values are presented as the
mean ± SD (n = 3). *p < 0.05. d V–G staining images at 4 weeks after transplantation. Top: CCD1 group. Middle: CCD2 group. Lower: Rev1 group.
Magnified images of the new bone area are shown on the right. BMC bone mineral content, BMD bone mineral density, BV bone volume, EB
embryoid body, NC nontransplanted defect (negative control), FIT fibroblast growth factor/insulin-like growth factor/transforming growth factor,
NT nontreated control, OBM osteoblast differentiation medium
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can generate unlimited quantities of cells. Furthermore,
genetic manipulations, such as the introduction of
exogenous genes and specific correction of a defined
mutation in established iPSCs, could lead to novel cellular
therapies. To date, there have been few reports of success-
fully generated corrected iPSCs (Rev-iPSCs) from patients
[34–37]. Another important reason to generate Rev-iPSCs
is their utility as a control for patient-derived iPSCs in re-
search. Therefore, we established Rev-iPSCs as control
cells from these CCD-iPSCs using the CRISPR/Cas tool.
RUNX2–HD protein complexes regulate target genes,
and RUNX2 has been characterized as a major hub of
HD protein regulation [29, 38–41]. Hojo et al. also
reported that osterix (Osx) is restricted to bone-forming
vertebrates, where it acts as a Dlx co-factor in OB speci-
fication [39]. We investigated major HD proteins in
osteogenesis from human-derived iPSCs and found that
insufficiency of RUNX2 might disrupt the early osteo-
genic circuitry for commitment of the bone cell pheno-
type in the differentiation from iPSC to osteolineage
cells. Recent reports also described that aged mice
required full Runx2 gene dosage for cancellous bone
regeneration after bone marrow ablation [42]. Experi-
ments with a calvarial bone defect model using severe
combined immunodeficiency rats to transplant CCD-
OBs showed poor bone formation, while reverted
CCD-OBs showed substantially improved bone regener-
ation. However, there was no significant difference in
BMD among all three groups. Thus, RUNX2 may have a
weak effect on BMD owing to its regulation, which
covers a relatively early stage, but not late stage, of
osteoblast differentiation. These findings suggest that
the haploinsufficiency of RUNX2 has a significant effect
on the early stage of membrane ossification, which
causes clinical symptoms in patients with CCD, and that
reverted iPSCs provide an iPSC-based novel therapeutic
option for the treatment of CCD.
Conclusions
iPSCs were generated from patients with CCD, and
Rev-iPSCs with corrected mutations were created by
CRISPR/Cas-mediated genome editing. These iPSCs can
not only provide a useful disease model to elucidate the
role of RUNX2 in osteoblastic differentiation but also
raise the tantalizing prospect that reverted iPSCs might
provide a practical medical treatment for CCD.
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